These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22532845)

  • 1. Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia.
    Grzywnowicz M; Zaleska J; Mertens D; Tomczak W; Wlasiuk P; Kosior K; Piechnik A; Bojarska-Junak A; Dmoszynska A; Giannopoulos K
    PLoS One; 2012; 7(4):e35178. PubMed ID: 22532845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia.
    Gamaleldin MA; Ghallab OM; Nadwan EA; Abo Elwafa RA
    Clin Transl Oncol; 2021 Nov; 23(11):2309-2322. PubMed ID: 34120295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.
    Brusa D; Serra S; Coscia M; Rossi D; D'Arena G; Laurenti L; Jaksic O; Fedele G; Inghirami G; Gaidano G; Malavasi F; Deaglio S
    Haematologica; 2013 Jun; 98(6):953-63. PubMed ID: 23300177
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
    Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.
    Lewinsky H; Barak AF; Huber V; Kramer MP; Radomir L; Sever L; Orr I; Mirkin V; Dezorella N; Shapiro M; Cohen Y; Shvidel L; Seiffert M; Herishanu Y; Becker-Herman S; Shachar I
    J Clin Invest; 2018 Dec; 128(12):5465-5478. PubMed ID: 30277471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [PD-1/PD-L1 expression and its implications in patients with chronic lymphocytic leukemia].
    Li JH; Pang NN; Zhang ZH; Zhang R; Chen G; Qu JH
    Zhonghua Xue Ye Xue Za Zhi; 2017 Mar; 38(3):198-203. PubMed ID: 28395442
    [No Abstract]   [Full Text] [Related]  

  • 8. CD4+ T Cells are Exhausted and Show Functional Defects in Chronic Lymphocytic Leukemia.
    Allahmoradi E; Taghiloo S; Tehrani M; Hossein-Nattaj H; Janbabaei G; Shekarriz R; Asgarian-Omran H
    Iran J Immunol; 2017 Dec; 14(4):257-269. PubMed ID: 29276179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PD-1/PD-L1 axis contributes to immune metabolic dysfunctions of monocytes in chronic lymphocytic leukemia.
    Qorraj M; Bruns H; Böttcher M; Weigand L; Saul D; Mackensen A; Jitschin R; Mougiakakos D
    Leukemia; 2017 Feb; 31(2):470-478. PubMed ID: 27479178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
    Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
    Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 is highly expressed by neoplastic B-cells in Richter transformation.
    Behdad A; Griffin B; Chen YH; Ma S; Kelemen K; Lu X; Chen QC
    Br J Haematol; 2019 Apr; 185(2):370-373. PubMed ID: 30028010
    [No Abstract]   [Full Text] [Related]  

  • 12. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
    Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
    Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma.
    Yokoyama S; Miyoshi H; Nakashima K; Shimono J; Hashiguchi T; Mitsuoka M; Takamori S; Akagi Y; Ohshima K
    Clin Cancer Res; 2016 Sep; 22(18):4727-34. PubMed ID: 27166394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
    Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
    Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.
    Grywalska E; Smarz-Widelska I; Korona-Głowniak I; Mertowski S; Gosik K; Hymos A; Ludian J; Niedźwiedzka-Rystwej P; Roliński J; Załuska W
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33121190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PD-1/PD-L1 Inhibitory Pathway is Altered in Primary Glomerulonephritides.
    Grywalska E; Smarz-Widelska I; Krasowska-Zajac E; Korona-Glowniak I; Zaluska-Patel K; Mielnik M; Podgajna M; Malm A; Rolinski J; Zaluska W
    Arch Immunol Ther Exp (Warsz); 2018 Apr; 66(2):133-143. PubMed ID: 28770269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia.
    McClanahan F; Hanna B; Miller S; Clear AJ; Lichter P; Gribben JG; Seiffert M
    Blood; 2015 Jul; 126(2):203-11. PubMed ID: 25800048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
    McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
    Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
    Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
    Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expansion of effector T cells associated with decreased PD-1 expression in patients with indolent B cell lymphomas and chronic lymphocytic leukemia.
    Tonino SH; van de Berg PJ; Yong SL; ten Berge IJ; Kersten MJ; van Lier RA; van Oers MH; Kater AP
    Leuk Lymphoma; 2012 Sep; 53(9):1785-94. PubMed ID: 22397719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.